Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 2 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 11 patents granted in the last 365 days
Wigen Biomedicine Technology (Shanghai) Co. Ltd. is navigating 5 pending office actions within the Biotechnology & Pharmaceuticals sector. These matters are handled by 5 distinct examiners, ensuring that each pending action is reviewed by a different official. This distribution spans 2 distinct art units, providing variety in the technical oversight of the portfolio. The presence of 2 distinct art units suggests that the company's pharmaceutical innovations are being evaluated across multiple specialized groups within the patent office. Practitioners should prepare for a decentralized prosecution experience where no single official's decision-making dominates the 5 pending office actions.
KUCHARCZK, JED A is identified as the busiest examiner, currently overseeing 1 pending office action. Given that 5 examiners are involved across the 5 total actions, the workload is evenly spread. This arrangement requires the applicant to manage 5 separate examiner relationships while adhering to the standards of 2 distinct art units. The 5 distinct examiners provide a broad range of perspectives on the company's biotechnology claims. This structure allows for independent evaluations of each filing, which can be advantageous for a diverse pharmaceutical portfolio. Practitioners must tailor their arguments to the specific technical requirements of each art unit and the individual preferences of the 5 examiners.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (20%) |
| §103 only | 2 (40%) |
| Multi-statute (no §101) | 2 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KUCHARCZK, JED A | 1 | 80.2% | +16.7% |
| RAO, SAVITHA M | 1 | 60.7% | +30.2% |
| MAHLUM, JONATHAN DAVIS | 1 | 51.4% | +25.6% |
| NOTTINGHAM, KYLE GREGORY | 1 | 61.7% | +31.9% |
| DEKARSKE, MADELINE MCGUIRE | 1 | 0.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18039229 | NOVEL CAMPTOTHECIN DERIVATIVE, COMPOSITION COMPRISING SAME AND USE THEREOF | DEKARSKE, MADELINE MCGUIRE | 13d |
| 18845669 | KIF18A INHIBITOR | KUCHARCZK, JED A | — |
| 18838598 | COMPOUND AS FAK INHIBITOR AND USE THEREOF | RAO, SAVITHA M | — |
| 18706531 | COMPOUNDS USED AS SRC INHIBITORS | MAHLUM, JONATHAN DAVIS | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18845669 | KIF18A INHIBITOR | KUCHARCZK, JED A | — |
| 18838598 | COMPOUND AS FAK INHIBITOR AND USE THEREOF | RAO, SAVITHA M | — |
| 18706531 | COMPOUNDS USED AS SRC INHIBITORS | MAHLUM, JONATHAN DAVIS | — |
| 18578384 | NAPHTHYRIDINE DERIVATIVE AS ATR INHIBITOR AND METHOD FOR PREPARING SAME | NOTTINGHAM, KYLE GREGORY | — |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18845669 | KIF18A INHIBITOR | KUCHARCZK, JED A | — | §102§112 | Non-Final OA | — | Pending | Sep 10, 2024 |
| 18838598 | COMPOUND AS FAK INHIBITOR AND USE THEREOF | RAO, SAVITHA M | — | §101§112 | Non-Final OA | — | Pending | Aug 14, 2024 |
| 18706531 | COMPOUNDS USED AS SRC INHIBITORS | MAHLUM, JONATHAN DAVIS | — | §103§112 | Non-Final OA | — | Pending | May 01, 2024 |
| 18578384 | NAPHTHYRIDINE DERIVATIVE AS ATR INHIBITOR AND METHOD FOR PREPARING SAME | NOTTINGHAM, KYLE GREGORY | 1621 | §103 | Final Rejection | — | Pending | Jan 11, 2024 |
| 18039229 | NOVEL CAMPTOTHECIN DERIVATIVE, COMPOSITION COMPRISING SAME AND USE THEREOF | DEKARSKE, MADELINE MCGUIRE | 1622 | §103 | Final Rejection | 13d | Pending | May 27, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial